Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to 0.32%.

  • Kymera Therapeutics' Return on Capital Employed fell 900.0% to 0.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.32%, marking a year-over-year decrease of 900.0%. This contributed to the annual value of 0.37% for FY2024, which is 400.0% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Return on Capital Employed stood at 0.32%, which was down 900.0% from 0.33% recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Return on Capital Employed registered a high of 0.13% during Q1 2021, and its lowest value of 0.37% during Q3 2023.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.29% (2022), whereas its average is 0.27%.
  • Per our database at Business Quant, Kymera Therapeutics' Return on Capital Employed tumbled by -1400bps in 2022 and then surged by 1400bps in 2024.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Return on Capital Employed stood at 0.19% in 2021, then tumbled by -55bps to 0.29% in 2022, then fell by -18bps to 0.35% in 2023, then increased by 19bps to 0.28% in 2024, then dropped by -14bps to 0.32% in 2025.
  • Its Return on Capital Employed was 0.32% in Q3 2025, compared to 0.33% in Q2 2025 and 0.31% in Q1 2025.